Miltefosine: oral treatment of leishmaniasis (Q36441483)

14 August 2017

1 reference

title

Miltefosine: oral treatment of leishmaniasis (English)

1 reference

14 August 2017

1 reference

Jaime Soto

1

1 reference

ORCID Public Data File 2021

author name string

Paula Soto

series ordinal

2

1 reference

14 August 2017

1 April 2006

1 reference

Expert Review of Anti-infective Therapy

14 August 2017

1 reference

14 August 2017

4

1 reference

14 August 2017

2

1 reference

14 August 2017

177-185

1 reference

Drug resistance in Indian visceral leishmaniasis

14 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Fatal case during treatment of american tegumentary leishmaniasis with sodium stibogluconate bp 88 (shandong xinhua)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Sodium stibogluconate cardiotoxicity and safety of generics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Progress in the treatment of a neglected infectious disease: visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Miltefosine: an oral drug for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Advances in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

The increase in risk factors for leishmaniasis worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Leishmaniasis: current situation and new perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

The epidemiology and control of leishmaniasis in Andean countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Therapeutic potential of terbinafine in subcutaneous and systemic mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Antiprotozoal activities of phospholipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Miltefosine to treat leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Challenges and new discoveries in the treatment of leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Chemotherapy of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Programmed cell death in procyclic form Trypanosoma brucei rhodesiense --identification of differentially expressed genes during con A induced death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Mechanisms of action of phospholipid analogs as anticancer compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Cell membranes and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): cellular and ultrastructural analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

Opportunities and Challenges in Antiparasitic Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.2.177

21 January 2018

Identifiers

DOI

10.1586/14787210.4.2.177

1 reference

14 August 2017

1 reference

PubMed ID

16597200